Rolf Jansson appointed acting Managing Director of Leipurin
Stock exchange release
September 23, 2022 at 1 p.m.
Rolf Jansson appointed acting Managing Director of Leipurin
The last workday of Heli Arantola, CEO of Aspo Group subsidiary Leipurin, has been specified as September 30, 2022. As announced on Aspo’s stock exchange release on June 27, 2022, Arantola has resigned to join another company.
Aspo Group’s CEO Rolf Jansson will take on the role of acting Managing Director of Leipurin from October 1, 2022. In addition, Aspo’s Vice President of Corporate Development Mikko Heikkilä takes responsibility for Leipurin’s selected strategic projects. The selection process for Leipurin’s new Managing Director is underway.
Further information, please contact:
Rolf Jansson, CEO, Aspo Plc, tel. +358 400 600 264, firstname.lastname@example.org
Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these aiming to be forerunners in sustainability. Aspo supports its businesses profitability and growth with the right capabilities. Aspo Group has businesses in 18 different countries, and it employs a total of approximately 900 professionals.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sampo plc’s share buybacks 02/12/20225.12.2022 07:30:00 CET | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 05/12/2022 at 08:30 am Sampo plc’s share buybacks 02/12/2022 On 02/12/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)13,82248.47AQEU30,08648.47CEUX15,16048.50TQEX71,56748.46XHELTOTAL130,63548.47 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 16,932,474 Sampo A shares representing 3.18 per cent of the total number of shares in Sampo plc. Details of
CGG Announces New Integrated Multi-Client Data Project in Southeast Arizona to Support Mining Industry5.12.2022 07:30:00 CET | Press release
Paris, France – December5, 2022 CGG, a global technology and Earth sciences leader, has announced a new multi-client data project in Southeast Arizona focusing on exploration and development in the mining industry. The project, supported by industry funding and available to license now, will begin immediately, with final products scheduled for delivery through CGG’s proprietary GeoVerse™ platform. Dechun Lin, EVP, Earth Data, CGG, said: “Our Southeast Arizona data project represents a significant step forward in our strategy to provide integrated data solutions for the mining industryand is an innovative and effective model to improve data access in critical mining regions.” As part of this project, CGG will acquire over 270,000 line-kilometers of new airborne multi-physics data, including aeromagnetic, radiometric and airborne gravity data. CGG’s extensive team of subsurface experts and data scientists will integrate this data set with 50,000 km2 of satellite imagery, multispectral da
Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer5.12.2022 07:15:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been treated with androgen-receptor pathway inhibitor (ARPI) therapy1 Pluvicto becomes the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy1, addressing a significant unmet need2 Findings to be presented at an upcoming medical meeting and submitted to regulatory authorities for approval in 2023 Novartis is advancing a broad portfolio of radioligand therapies to treat cancer and is investing in manufacturing capacity to meet the growing global demand for treatment Basel, December 5, 2022 — Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. Pluvic
Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning5.12.2022 07:00:00 CET | Press release
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first approved dual orexin receptor antagonist, offers a new targeted mechanism of action that decreases nighttime overactive wakefulness in insomniaIdorsia Switzerland – led by General Manager Alice Huisman – aims to make QUVIVIQ available to patients with chronic insomnia disorder in Switzerland around mid-2023 Allschwil, Switzerland – December 5, 2022 Idorsia Ltd (SIX: IDIA) today announced that Swissmedic has granted marketing authorization for QUVIVIQ™ (daridorexant) for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.1 Chronic insomnia disorder is one of the most prevalent sleep disorders in Europe, affecting between 6%-12% of the adult population,2 and impacting both physical an
ForFarmers N.V.: ForFarmers convenes Extraordinary General Meeting of Shareholders on 17 January, 20235.12.2022 07:00:00 CET | Press release
Lochem, 5 December, 2022 ForFarmers convenesExtraordinary General Meeting of Shareholders on17 January, 2023 ForFarmers N.V. announces that Extraordinary General Meeting of Shareholders will be held (as a virtual meeting) on Tuesday 17 January, 2023, starting at 10.00 am (CET) in relation to the appointment of Theo Spierings as member of the Executive Board (CEO). The convocation announcement and the agenda and explanatory notes to the agenda are available via the corporate website of ForFarmers (www.forfarmersgroup.eu/en) under Investors / General Meeting of Shareholders. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For additional information: Caroline Vogelzang, Director Investor Relations M: 0031 6 10 94 91 61 E: email@example.com Company profile ForFarmers N.V. (‘ForFarmers’, Lochem, the Netherlands) is an internationally operating feed